Quick Answer
Actinium Pharmaceuticals, Inc. reported Operating Income Loss of -$36.25 million for the year ending 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +13.9% in Operating Income Loss from 2024 to 2025.
- This data is from Actinium Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Actinium Pharmaceuticals, Inc.'s Operating Income Loss has declined by 139,027.9%.
- Historical annual values: Fiscal year 2025: -$36.25 million | Fiscal year 2024: -$42.12 million | Fiscal year 2023: -$51.92 million | Fiscal year 2022: -$34.10 million | Fiscal year 2021: -$24.96 million | Fiscal year 2020: -$22.39 million | Fiscal year 2019: -$22.07 million | Fiscal year 2018: -$23.83 million | Fiscal year 2017: -$26.91 million | Fiscal year 2016: -$26.85 million | Fiscal year 2015: -$24.83 million | Fiscal year 2014: -$22.48 million | Fiscal year 2013: -$6.59 million | Fiscal year 2012: -$7.95 million | Fiscal year 2011: -$3.28 million | Fiscal year 2010: -$26.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: